Sandoz announced today that it has resubmitted to the FDA its Biologics License Application (BLA) for its proposed biosimilar pegfilgrastim.
Sandoz announced today that it has resubmitted to the FDA its Biologics License Application (BLA) for its proposed biosimilar pegfilgrastim.
In July 2016, Sandoz revealed that it had received a Complete Response Letter for the proposed biosimilar, and stated at the time that it was working with the FDA to address the agency’s concerns. The newly resubmitted BLA includes new data from a pivotal pharmacokinetic (PK) and pharmacodynamic (PD) study.
The study was a single-dose, 3-period crossover study that compared the proposed biosimilar with the US-sourced and EU-sourced reference pegfilgrastim, Neulasta, and compared the US- and EU-sourced references.1
In a statement announcing the resubmission, Mark Levick, MD, PhD, global head of development, biopharmaceuticals, Sandoz, said, “The US market is just beginning to benefit from biosimilars, as shown by the success of our filgrastim, the first approved biosimilar in the [United States]. The submission of our pegfilgrastim biosimilar application is another step for us as we continue to lead the way in creating early and expanded patient access to life-changing biologics.”
A previous study in healthy volunteers determined PK similarity, given that the 90% CI for the geometric mean ratio of the biosimilar versus the reference was within the prespecified similarity margin of 0.8-1.25. It also concluded that there was PD similarity between the products, given that the 95% CI for the ratio of the biosimilar versus the reference was within the same prespecified similarity margin.2
The new study was designed to address the high inter-subject variability (ISV) linked to target-mediated clearance with pegfilgrastim; the 3-way crossover design of the new study was intended to address ISV, as well as to provide a bridge between the EU and US reference pegfilgrastim products.
The molecule has also been studied in phase 3 clinical trials in patients undergoing chemotherapy.
Sandoz’s pegfilgrastim biosimilar is already approved in the European Union, where it received a marketing authorization in November 2018 under the name Ziextenzo.
References
1. R Nakov, S Schussler, S Schier-Mumzhiu, et al. A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: methodological approach. Ann Oncol. 2018;29(8)mdy300.110. doi: 10.1093/annonc/mdy300.110.
2. Nakov R, Gattu S, Wang J, Velinova M, Skerjanec A. Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects [abstract]. Cancer Res. 2018;78(4):nr P3-14-10. doi: 10.1158/1538-7445.SABCS17-P3-14-10.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.